Skip to main content
. Author manuscript; available in PMC: 2013 Jun 21.
Published in final edited form as: Cancer Lett. 2010 Jul 31;298(2):212–221. doi: 10.1016/j.canlet.2010.07.007

Fig. 3.

Fig. 3

Fig. 3

Caspase-3 activation in decursin-induced apoptosis in KBM-5 cells. (A) Cells were treated with 0, 20, 40 or 80 μM decursin for 24 h and Western blotting was performed for cleaved caspase-3, cleaved caspase-9 and PARP. (B) Cells were treated with 80 μM decursin for 0, 6, 18 or 24 h and Western blotting was performed for cleaved caspase-3, cleaved caspase-9 and PARP. (C) Cells were treated with or without 80 μM decursin for 24 h and immunostained for cleaved caspase-3. The immunostained cells were mounted in medium containing DAPI and visualized under a Carl Zeiss LSM5 confocal microscope. (D) Cells were pretreated with or without caspase-3 inhibitor for 1 h and then treated with 80 μM decursin for 24 h. Western blotting was performed for cleaved caspase-3 and PARP. (E) Cells were treated with 80 μM decursin for 0, 6, 18 or 24 h and Western blotting was performed for c-IAP1, c-IAP2, Bcl-2 and Bcl-xL.